Xenon Pharmaceuticals Inc
NASDAQ:XENE

  • LAST PRICE
    40.3300
  • TODAY'S CHANGE (%)
    -0.0100 (-0.0248%)
  • Bid / Lots
    40.3300/ 1
  • Ask / Lots
    40.5800/ 4
  • Open / Previous Close
    40.0800 / 40.3400
  • Day Range
    40.0800
    40.4500
  • 52 Week Range
    27.9850
    50.9900
  • Volume
    2,778

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
XENE
Xenon Pharmaceuticals Inc
3.0B
-14.9x
---
VSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
APGE
Apogee Therapeutics Inc
3.1B
-30.8x
---
SMMT
Summit Therapeutics Inc
3.2B
-3.0x
---
IOVA
Iovance Biotherapeutics Inc
2.9B
-5.8x
---
IDYA
IDEAYA Biosciences Inc
3.1B
-20.5x
---
As of 2024-05-17

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

Chairman of the Board
Simon Pimstone
President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$3.0B
Revenue (TTM)
$0.00
Shares Outstanding
75.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.23
EPS
$-2.71
Book Value
$12.31
P/E Ratio
-14.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.